SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-17-115091
Filing Date
2017-04-07
Accepted
2017-04-07 09:23:55
Documents
1
Group Members
EDWIN M. KANIA, JR.FLAGSHIP VENTURES 2007 GENERAL PARTNER LLCFLAGSHIP VENTURES FUND IV GENERAL PARTNER LLCFLAGSHIP VENTURES FUND IV, L.P.FLAGSHIP VENTURES FUND IV-RX, L.P.NOUBAR B. AFEYAN, PH.D.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 5 TO SCHEDULE 13D d366869dsc13da.htm SC 13D/A 121546
  Complete submission text file 0001193125-17-115091.txt   123322
Mailing Address 245 FIRST STREET SUITE 1800 CAMBRIDGE MA 02142
Business Address 245 FIRST STREET SUITE 1800 CAMBRIDGE MA 02142 617-444-8550
Eleven Biotherapeutics, Inc. (Subject) CIK: 0001485003 (see all company filings)

IRS No.: 262025616 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87951 | Film No.: 17747871
SIC: 2834 Pharmaceutical Preparations

Mailing Address 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02142 617-868-1888
Flagship Ventures Fund 2007, L.P. (Filed by) CIK: 0001508052 (see all company filings)

IRS No.: 260552049 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A